Dr. Kimberly R. Kruczek
Claim this profileIngalls Memorial Hospital
Studies Breast Cancer
Studies Squamous Cell Carcinoma
7 reported clinical trials
18 drugs studied
Area of expertise
1Breast Cancer
Stage IV
Stage III
PD-L1 negative
2Squamous Cell Carcinoma
Stage IV
PD-L1 positive
PD-L1 negative
Affiliated Hospitals
Clinical Trials Kimberly R. Kruczek is currently running
Olanzapine vs Megestrol Acetate
for Cancer-Related Anorexia
This trial tests whether olanzapine or megestrol acetate is better at increasing appetite in patients with advanced cancer. These patients often struggle with eating and weight loss. Both medications aim to make them feel hungrier, helping them eat more and gain weight. Megestrol acetate is known for its effectiveness in increasing appetite in patients with cancer.
Recruiting2 awards Phase 31 criteria
Venetoclax + Obinutuzumab
for Leukemia
This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with the venetoclax and obinutuzumab early (before patients have symptoms) may have better outcomes for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma compared to starting treatment with the venetoclax and obinutuzumab after patients show symptoms.
Recruiting2 awards Phase 31 criteria
More about Kimberly R. Kruczek
Clinical Trial Related6 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Kimberly R. Kruczek has experience with
- Pembrolizumab
- Carboplatin
- Nivolumab
- Ladiratuzumab Vedotin
- Cisplatin
- Tisotumab Vedotin
Breakdown of trials Kimberly R. Kruczek has run
Squamous Cell Carcinoma
Colorectal Cancer
Lung Cancer
Pancreatic Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Kimberly R. Kruczek specialize in?
Kimberly R. Kruczek focuses on Breast Cancer and Squamous Cell Carcinoma. In particular, much of their work with Breast Cancer has involved Stage IV patients, or patients who are Stage III.
Is Kimberly R. Kruczek currently recruiting for clinical trials?
Yes, Kimberly R. Kruczek is currently recruiting for 2 clinical trials in Harvey Illinois. If you're interested in participating, you should apply.
Are there any treatments that Kimberly R. Kruczek has studied deeply?
Yes, Kimberly R. Kruczek has studied treatments such as Pembrolizumab, Carboplatin, Nivolumab.
What is the best way to schedule an appointment with Kimberly R. Kruczek?
Apply for one of the trials that Kimberly R. Kruczek is conducting.
What is the office address of Kimberly R. Kruczek?
The office of Kimberly R. Kruczek is located at: Ingalls Memorial Hospital, Harvey, Illinois 60426 United States. This is the address for their practice at the Ingalls Memorial Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.